Today

Agents

Chat

Arena

Discover

More

App

Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial - LABT News | Rallies

Lakewood-Amedex wins IRB approval for Phase 2a Nu-3 diabetic foot ulcer trial

LABT•2026-09-18

IRB clearance for Phase 2a trial

Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers.

All participating sites also secured IRB sign-off, clearing the way to start patient enrollment.

Related News

Sunstone Hotel Investors updates financial calendar with third-quarter earnings release and conference call

SHO•2026-09-18

Global rates reset, AI angst and oil's long haul: The financial week in five charts

SPY•2026-09-18

AbbVie says real-world studies show Vraylar improves symptoms in MDD, bipolar I depression

ABBV•2026-09-18

Foresight Automotive names Shlomo Hillel CTO as Levy Zruya resigns

FRSX•2026-09-18

Netflix dips after Wells Fargo downgrades stock, sees 'messier story'

NFLX•2026-09-18